BATCH OF 5 RESTYLANE LIDO EYELIGHT (1x0,5ml) GALDERMA

RESTYLANE LIDO EYELIGHT is a hyaluronic acid (HA) injectable dermal filler treatment. Safe and reliable, it works by reducing the lines caused by a lack of volume in the under-eye area. Cross-linked hyaluronic acid 20mg/ml + Lidocain 0,3%.

This pack contains

RESTYLANE LIDO EYELIGHT (1x0,5ml) GALDERMA

€64.00

€312.00 (tax incl.) €320.00 -2.5% €312.00 (tax excl.)

Tax excluded

Quantity

Description

RESTYLANE LIDO EYELIGHT (1x0,5ml) GALDERMA QMED

MEDICAL USE STRICT. Reserved for dermatologists and aesthetic doctors because they require a medical procedure. Hyaluronic Acid Dermal Filler Injectable Gel with LIDOCAIN. RESTYLANE is a product developed for aesthetic purposes.

DESCRIPTION

RESTYLANE LIDO EYELIGHT is a hyaluronic acid (HA) injectable dermal filler treatment.
Safe and reliable, it works by reducing the lines caused by a lack of volume in the under-eye area.
RESTYLANE LIDO EYELIGHT injectable gel is designed to temporarily restore volume to the hollows under the eyes in patients over the age of 21.
RESTYLANE EYELIGHT is intended for patients that are beginning to see a hollow appearance under the eyes.
RESTYLANE LIDO EYELIGHT has been shown to maintain this effect for up to 12 months.

DESCRIPTION:

RESTYLANE LIDO EYELIGHT is a unique form of non-animal, stabilized hyaluronic acid (NASHA). Hyaluronic acid is a natural polysaccharide which occurs as an important structural element in the skin and in subcutaneous andconnective tissues as well as in the synovial tissue and fluid. Hyaluronic acid belongs to a group ofvery few substances which are identical in all living organisms. Tired-looking eyes is a very common problem.

PRESENTATION RESTYLANE LIDO EYELIGHT:

RECOMMENDED NEEDLES: 29G 1/2 Steriglide 25G.
SYRINGE VOLUME: BLISTER PACK.
Single-use glass syringe containing 0,5 ml.
1 syringe pre-filled.
Technologie: NASHA (Non Animal Stabilized Hyaluronic Acid).
RESTYLANE LIDO EYELIGHT is a clear, transparent and viscous gel supplied in a glass syringe together with a 29G Thin Wall (TW) or 30G needle(s).
The product is for single use only.
TYPES OF SKINS: Normal to thick skin.

COMPOSITION RESTYLANE LIDO EYELIGHT:

Cross linked hyaluronic acid 20 mg/mL stabilized Technologie NASHA + Lidocain 0,3%.

Lidocaine hydrochloride 0.3%.
Phosphate buffered saline pH 7 qs ad 0,5ml.
HA CONCENTRATION: 20mg/ml HYALURONIC ACID.
DEGREE OF RETICULATION: 5/5.
PARTICLE CALIBRATION: 1/3.
LIFTING CAPACITY: Volume effect MODERATE.
GEL TEXTURE: FIRMNESS VISCOSITY FIRM.
DURATION: 9-12 months.
DEPTH OF INJECTION: Dermis.

MODE OF ACTION:

RESTYLANE LIDO EYELIGHT acts by adding volume to the tissue, thereby restoring the skin contours or enhancing the lips to the desired level of correction.
RESTYLANE LIDO EYELIGHT is naturally integrated into the tissue and will in time undergo iso volemic degradation.
RESTYLANE LIDOCAINE has been enhanced with the addition of Lidocaine in order to reduce patient discomfort during treatment.

COMPOSITION OF THE GEL HA:

Hyaluronic acid (HA) dermal biphasic fillers are synthesized for their efficacy in correcting aesthetic defects such as wrinkles, scars and facial contouring defects.
The fillers consist of crosslinked HA microspheres suspended in a noncrosslinked HA.
To extend the duration of HAs within the dermis and obtain the particle texturing feel, HAs are crosslinked to obtain the suitable mechanical properties.

INDICATION AND USAGE:

FOR TREATMENT OF FINE LINES, WRINKLES AND FOLDS. RESTYLANE is intended to be used for facial tissue augmentation.
RESTYLANE LIDOCAINE is intended to be used for facial tissue augmentation.
It is recommended that the product be used for the correction of wrinkles and for lip enhancement.
RESTYLANE should be injected into the middle part of the dermis layer of the facial skin or in the submucosal layer of the lip.
RESTYLANE was the first product of its type and is now seen as the gold standard for diminishing moderate lines and wrinkles, such as those between the eyebrows, on the forehead and the bilateral lines between the nose and mouth.

ZONE D'INJECTION:

Mid derm/ Supra périoté: zone péri-orbitaire. It should be injected into the middle part of the dermis layer of the facial skin. Deeper injections into the subcutaneous fatty tissue or supraperiosteal layer are appropriate for areas with adequate soft tissue support and soft tissue cover such as midface and jaw line.